Rising Biosciences (Rising Biosciences) EV-to-EBITDA : (As of Jun. 17, 2024)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rising Biosciences's enterprise value is $0.00 Mil. Rising Biosciences does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Rising Biosciences's EV-to-EBITDA at this moment.

The historical rank and industry rank for Rising Biosciences's EV-to-EBITDA or its related term are showing as below:

RBII's EV-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 14.43
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-17), Rising Biosciences's stock price is $0.0001. Rising Biosciences does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Rising Biosciences's PE Ratio at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Rising Biosciences EV-to-EBITDA Historical Data

The historical data trend for Rising Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences EV-to-EBITDA Chart

Rising Biosciences Annual Data

Trend

EV-to-EBITDA

Rising Biosciences Quarterly Data

EV-to-EBITDA

Competitive Comparison of Rising Biosciences's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's EV-to-EBITDA falls into.

Rising Biosciences EV-to-EBITDA Calculation

Rising Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.000	/
	=

Rising Biosciences (GREY:RBII) EV-to-EBITDA Explanation

Rising Biosciences's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.0001	/
	=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Rising Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » EV-to-EBITDA

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.